Related Experiment Video
Updated: May 4, 2026
13:59
High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
Published on: August 18, 2023
3.0K
Marked radiographic response of a HER-2-overexpressing biliary cancer to trastuzumab
1Washington University School of Medicine, Department of Oncology, St Louis, MO, USA.
Cancer Management and Research
|December 31, 2013
Abstract:
Trastuzumab is a monoclonal antibody targeting HER-2. HER-2 overexpression has been described in gallbladder cancer and in cholangiocarcinoma. This report describes the first case of a patient with HER-2 overexpressing metastatic gallbladder adenocarcinoma and responding radiographically and biochemically to trastuzumab alone.
